Bio-Bridge Science Signs a Non-Binding MOU to form a Joint Venture in China

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), 
      a biotechnology company engaged in the commercial development of 
      vaccines for the prevention and treatment of human infectious diseases 
      announced today that it has entered into a non-binding memorandum of 
      understanding (the "MOU") with JR Scientific, Inc., a Woodland, 
      California based manufacturer of classical and custom cell culture 
      medium and sera products ("JRS”) and Mr. 
      Jan Baker, President and CEO of JRS. Under the MOU, Bio-Bridge Science 
      will form a joint venture (the "JV") together with JRS and several other 
      investors in China. The JV is expected to mainly produce culture medium, 
      serum, and other biomaterial for sale in China and other countries under 
      the brand name of the JV. Cell culture medium and serum are used in 
      vaccine production as well as scientific research. JRS and Mr. Baker as 
      part of the MOU, agree to transfer technology and “know-how” 
      to the JV. The total investment for the JV is planned to be around RMB 
      10 million (US about $1.4 million). Dr. Liang Qiao, Chairman and CEO of 
      Bio-Bridge said, “We are excited to work with 
      Mr. Baker, JRS, and other investors to form this JV. The JV will fit 
      into our strategic plan by providing a potential source of revenue as 
      well as vaccine material for our own vaccine research and production.”
    
    
      Acquisition Update
    
    
      The acquisition of a majority shareholding in Inner Mongolia Xinheng 
      Baide Biotechnology Co., Ltd. reported in our 2007 fiscal year Form 
      10-KSB is proceeding. Xinheng Baide is a bovine serum producer based in 
      Inner Mongolia, China. Bovine serum is used in vaccine production as 
      well as scientific research. Bio-Bridge Science is finalizing its due 
      diligence and expects to execute the definitive acquisition agreement 
      before the end of April 2008. The Xinheng Baide acquisition is expected 
      to provide Bio-Bridge with increasing revenues in the future as the 
      demand for bovine serum increases.
    
    
      Beijing GMP Facility Completion Update
    
    
      Bio-Bridge signed a contract in March of 2008 with a local electricity 
      construction company and the electricity construction work for Bio-Bridge’s 
      GMP facility in Tianzho (Beijing) is currently underway. Bio-Bridge 
      projects that the facility will be operational for producing vaccines 
      for clinical trial purposes in the second half of 2008.
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.